<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290886</url>
  </required_header>
  <id_info>
    <org_study_id>CeTMAd/ELA/2011</org_study_id>
    <nct_id>NCT02290886</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral</brief_title>
  <official_title>A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to&#xD;
      evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal&#xD;
      stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to&#xD;
      evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal&#xD;
      stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).&#xD;
&#xD;
      40 patients will be enrolled and will be randomized into one of the following 4 arms:&#xD;
&#xD;
        -  10 patients in the control group (placebo)&#xD;
&#xD;
        -  10 patients received a dose of 1 million MSC / kg&#xD;
&#xD;
        -  10 patients received a dose of 2 million MSC / kg.&#xD;
&#xD;
        -  10 patients received a dose of 4 million MSC / kg&#xD;
&#xD;
      The follow-up phase of each patient from the cell infusion/placebo will be 6 months.&#xD;
&#xD;
      At the time that each patient completed the follow-up period (i.e., 6 months after the&#xD;
      infusion of the cellular product or placebo), the blind will be open, and patients who have&#xD;
      been assigned to the control group, will receive the cell product as secondary treatment.&#xD;
      These patients will be randomized to receive each of the doses used in the first phase. From&#xD;
      this point, they begin a second period of follow up of 6 months.&#xD;
&#xD;
      In addition, after 6 months of MSC infusion, every patient will continue in an open extension&#xD;
      study for 36 months to assess the safety of MSC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells (MSC) from adipose tissue in patients with Amyotrophic lateral Sclerosis (ALS) ABSENCE of: complications in the place of the infusion, appearance of a new neurological effect not attributable to the natural progression of this pathology and adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications in the place of the infusion</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance of a new neurological effect not attributable to the natural progression of this pathology</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the safety of the intravenous administration of 3 doses of autologous</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the progression of the disease (modifications in the scale of functionality of the ALS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the degree of muscular force</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the vital forced capacity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurophysiological parameters and of quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need and time to tracheotomy or permanent assisted ventilation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 1 million of MSC/ kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 2 million of MSC/ kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 million of MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of 4 million of MSC/ kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous administration of placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 1 million of MSC</intervention_name>
    <arm_group_label>1 million of MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 2 million of MSC</intervention_name>
    <arm_group_label>2 million of MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous administration of 4 million of MSC</intervention_name>
    <arm_group_label>4 million of MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women and males over 18-year-old.&#xD;
&#xD;
          2. Good understanding of the protocol and aptitude to grant the informed assent.&#xD;
&#xD;
          3. Diagnosis of sporadic ALS, with diagnosis of certainty, that is to say, definite or&#xD;
             probable, in agreement with the criteria of &quot;El Escorial&quot;, of the World Federation of&#xD;
             Neurology.&#xD;
&#xD;
          4. Forced vital capacity of at least 50 % of the one that would correspond to them for&#xD;
             sex, height and age.&#xD;
&#xD;
          5. More than 6 and less than 36 months of evolution of the disease (from the beginning of&#xD;
             the symptoms).&#xD;
&#xD;
          6. Possibility of obtaining, at least, 50gr of adipose tissue.&#xD;
&#xD;
          7. Treatment with riluzole, for at least, a month before the inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any concomitant disease that under investigator's criteria could concern the measures&#xD;
             of the clinical variables of the trial (hepatic, renal or cardiac insufficiency,&#xD;
             diabetes mellitus, etc).&#xD;
&#xD;
          2. Previous therapy with stem cells.&#xD;
&#xD;
          3. Participation in another clinical trial during 3 months previous to the entry in this&#xD;
             trial.&#xD;
&#xD;
          4. Any disease lymphoproliferative&#xD;
&#xD;
          5. Tracheostomy and /or gastrostomy.&#xD;
&#xD;
          6. Haemophilia, diathesis hemorrhagic or anticoagulative current therapy.&#xD;
&#xD;
          7. Hypersensitivity known to the bovine foetal whey or the gentamicin.&#xD;
&#xD;
          8. Medical precedents of infection of the HIV or any serious condition of&#xD;
             immunocompromised.&#xD;
&#xD;
          9. Positive HBV or HCV serology&#xD;
&#xD;
         10. Levels of creatinine in whey &gt; 3.0 in subjects not submitted to haemodialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Óscar Fernández, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Regional U. de Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Regional Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena, Servicio de Neurología</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety evaluation</keyword>
  <keyword>intravenous administration</keyword>
  <keyword>3 doses of autologous MSC</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

